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Objective Intramuscular (i.m.) pethidine is used worldwide for
labour analgesia and i.m. diamorphine usage has increased in the
UK in the last 15 years. This trial aims to ascertain the relative
efficacy and adverse effects of diamorphine and pethidine for
labour pain.
Design Prospective, parallel-arm randomised controlled trial with
blinding of participants, care-givers and outcome assessors.
Setting Maternity units in two District General Hospitals in the UK.
Population After written informed consent, 484 women were
randomised and recruited (244 diamorphine, 240 pethidine).
Inclusion criteria included women 16 years or older, established
labour, singleton pregnancy, 37–42 weeks of gestation and weight
60–120 kg.
Methods On request of i.m. analgesia, participants received either
150 mg pethidine or 7.5 mg diamorphine based on computer-
generated block randomisation.
Main outcome measures Maternal—reduction in pain intensity
from baseline (10-cm visual analogue scale) at 60 minutes and
over the 3-hour period after drug administration. Neonatal—
requirement for resuscitation and Apgar score at 1 minute.
Results Diamorphine provided modestly improved pain relief at
60 minutes, mean difference 1 cm (95% confidence interval [CI]
0.5–1.5), and over the 3 hours, mean difference 0.7 cm (95% CI
0.3–1.1). However, average length of labour in women receiving
diamorphine was 82 minutes longer (95% CI 39–124) and
therefore they experienced more pain overall. There were no
statistically significant differences in primary neonatal outcomes.
Conclusions There is a modest difference between the analgesia
provided by diamorphine or pethidine for labour analgesia but
diamorphine is associated with significantly longer labours.
Keywords Diamorphine, labour analgesia, meperidine, opiate,
pethidine.
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Introduction
Labour is a painful experience and analgesia is often
required. Most consultant-led obstetric units in the UK
offer intramuscular (i.m.) opioids as well as regional anal-
gesia. In the UK, 33% of women in labour use i.m. pethi-
dine and it is the only opioid licensed for independent use
by midwives.1 Pethidine, otherwise known as meperidine,
is a widely used i.m. analgesic for labour pain worldwide.
Research has demonstrated that pethidine provides variable
pain relief in labour; much of its effect is sedation rather
than analgesia.2,3 Pethidine also has adverse effects in both
the mother and neonate. It may cause nausea, vomiting
and dysphoria in women during labour.4 It crosses the pla-
centa and may cause reduced fetal heart rate variability and
fewer heart rate accelerations.5 Neonatal adverse effects
include respiratory depression, impaired breastfeeding and
altered crying.6,7
Despite the disadvantages of pethidine, there are few
well-designed studies comparing the relative adverse effects
and effectiveness of different opioids in labour. Systematic
reviews comparing parenteral opioids in labour have sug-
gested the need for well-designed and adequately powered
trials of pethidine versus other opioids.8,9 A small trial com-
paring i.m. pethidine with diamorphine, showed diamor-
phine to be more efficacious than pethidine when used for
labour analgesia in multiparous women, but not nullipa-
*The copyright line for this article was changed on 9 February 2015 after original online publication.
Trial Registration EudraCT No: 2006-003250-18; ISRCTN14898678; http://
www.controlled-trials.com/ISRCTN4898678.
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General obstetrics
rous women or both parities combined.10 The authors
suggested that their trial was underpowered. A national sur-
vey relating to the use of i.m. opioids for analgesia in
labour in the UK revealed that diamorphine was used in
34% of maternity units and this was a substantial increase
in usage.11 Where it is used, there is a perception that it
provides superior analgesia with fewer adverse effects than
pethidine, but there are no published large randomised
controlled trials to support this impression. We undertook
a two-centre blinded randomised controlled trial comparing
i.m. diamorphine and pethidine in labour, investigating
their analgesic efficacy and adverse effects in the mother,
fetus and neonate during the immediate peripartum period.
Methods
A detailed protocol for this trial was published before
completion of the trial and analysis of the data.12 This two-
centre blinded randomised controlled trial comparing i.m.
diamorphine and pethidine was conducted at Poole Hospi-
tal NHS Foundation Trust (PHFT) the sponsor site, with
5800 deliveries, and the Royal United Hospital, Bath
(RUH), 5300 deliveries per annum. Southampton and
South West Hampshire Ethics Committee granted
approval. Trial information was given to women and writ-
ten informed consent was obtained in the antenatal period
via clinics both in the community and in maternity hospi-
tals. Consented women in labour were recruited to the trial
on maternal request for opioid analgesia.
Inclusion criteria for randomisation included nulliparous
and multiparous women aged 16 years or older who had
given written informed consent, who were in active labour
defined as regular uterine contractions of at least two in
10 minutes, with a singleton pregnancy, cervical dilatation
of at least 3 cm, with gestation of 37–42 weeks, and weight
between 60 and 120 kg. The weight eligibility criterion was
reduced from 70 kg to 60 kg with a substantial amendment
in June 2009 approximately 3 months after the start of
recruitment. Exclusion criteria included allergy or previous
adverse reaction to opioids or opioid dependency, use of
parenteral opioids within the previous 24 hours or presence
of severe systemic disease.
Interventions
Either i.m. pethidine 150 mg or diamorphine 7.5 mg was
given into the muscles of the gluteus or lateral thigh by
the midwife looking after the women from the trial
syringes provided by the research midwife. These doses
were considered to be equivalent and commonly used
based on previous studies and from a national survey of
opioid use in obstetrics.10,11 A maximum of two doses of
opioid were given with a minimum interval of 2 hours if
the women requested additional analgesia. Women also
received metoclopramide 10 mg with the first dose. Regio-
nal analgesia or Entonox were available as rescue analgesia.
Randomisation and masking
The trial statistician provided the computer-generated
block randomisation using block sizes between two and ten
to ensure approximately equal group sizes, and stratified by
centre. The pharmacies of both trial centres prepared
batches of two identical syringes labelled only with the trial
number to conceal group allocation and to ensure that if
two doses were given, the same opioid was given both
times. This ensured that the women, researchers, maternity
unit staff and trial statistician were blinded to allocation.
Once recruited, women were randomly allocated to receive
either opioid. To further reduce bias the actual identities of
the two groups were not revealed until after full analysis
and discussion of the results.
Measurements
General demographics and measurements recorded included
age, weight, gestational age, cervical dilatation at first request
for analgesia, frequency of contractions, parity, spontaneous
or induced labour, use of oxytocin, fetal presentation and
position, and mode of delivery. Further details are given on
the data collection sheet (see Appendix S1).
Maternal primary outcomes
Pain severity during the last contraction was assessed using a
Visual Analogue Scale (VAS) (with anchor points of 0 = no
pain at all and 10 = the most excruciating pain) every
30 minutes during the 3-hour period after administration of
the trial drug. This information was used to derive measures
of pain relief at each time-point using absolute change in
pain intensity (on a 10-cm VAS) from pre-analgesia (base-
line). In addition to analysing all the time-points together (as
described in the section on statistical analysis), a specific
analysis of pain relief at 60 minutes was conducted, because
it was anticipated that the maximum analgesic effect would
occur then. Also, pain intensity at 60 minutes was the
primary outcome used by Fairlie et al.10
Neonatal primary outcomes
The primary neonatal outcomes were need for neonatal
resuscitation and Apgar score <7 at 1 minute.
Secondary outcomes
These are described in detail in the published protocol
and detailed results are presented in the Supplementary
material, Tables S2–S5.12 Maternal secondary outcome
measures included a four-point verbal pain intensity score
and a four-point verbal rating scale (VRS) for midwife
assessment of maternal pain relief. Other secondary mater-
nal outcome measures were sedation, haemoglobin oxygen
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saturation, nausea, vomiting, satisfaction with analgesia and
time from first dose to delivery. Neonatal secondary out-
come measures included cardiotocograph trace, umbilical
artery and vein pHs, time from delivery to first breath, Ap-
gar score at 5 minutes, naloxone use, haemoglobin oxygen
saturation, sedation, time from delivery to first feed and
midwife assessment of neonatal breastfeeding behaviour
during the first 2 hours after delivery.
Sample size
The sample size calculation was based on data from the
comparable trial of pethidine versus diamorphine by Fairlie
et al.10 With 406 women, the IDvIP trial was designed to
have 90% power (at the 5% significance level) to detect a
mean difference of 1 cm on a 10-cm VAS pain score and
to detect approximately 50% reduction in occurrence of
neonatal primary outcomes (see published protocol for fur-
ther rationale).12 Initially we planned to recruit 450 women
to allow for withdrawals and incomplete data, but
increased this to 484 towards the end of recruitment to
take into account the observed 16% proportion with miss-
ing data for pain at 60 minutes. No interim analysis was
planned or conducted.
Statistical analysis
A fuller description of the analysis plan is available in the
published protocol.12 Results are reported using CONSORT
guidelines.13 Women were analysed in the group to which
they were originally assigned, regardless of what subsequently
occured in labour. Missing maternal data were minimal
except for the 30-minute interval measurements. Maternal
data missing at 30 minutes and later was the result of the
need for maternal examination or other intervention or
immediate delivery. Data were analysed using IBM SPSS Ver-
sion 19 (IBM, Armonk, NY, USA), MLWiN version 2.17
(Centre for Multilevel Modelling, University of Bristol, Bris-
tol, UK), and STATA 11.2 (Stata Corp., College Station, TX,
USA). All analyses take into account the stratification vari-
able of recruitment centre. Binary outcomes were compared
between pain relief groups using logistic regression for single
measures and Generalised Estimating Equations for repeated
measures taken at 30-minute intervals. Continuous out-
comes were compared using multiple regression for single
measures and mixed models for repeated measures. Time
effects were modelled using a categorical indicator variable.
Further, prespecified analyses adjusting for maternal age,
parity, gestation and pre-administration pain intensity were
also conducted. These have not been reported unless they
changed results. In addition to the a priori analyses specified
in the protocol, area under the curve was used to compare
total pain experience over the 3-hour period to take into
account both amount and duration of pain (potential values
ranging from zero to 30).
Trial governance, sharing and rights to the data
A Data and Safety Monitoring Committee (DSMC) had a
remit to look at trial progress and adverse events. The
National Institute for Health Research (NIHR) grant
awarding body, Research for Patient Benefit, has rights of
access to the anonymised data as stated in Sections 9 and
10 of the contract agreement with the Sponsor, Poole
Hospital NHS Foundation Trust.
Results
A total of 1128 women were consented and 484 women were
recruited to the trial (Figure 1). Two hundred and forty-four
women were randomly allocated to the diamorphine group
and 240 to the pethidine group. Baseline characteristics were
comparable between the two groups (Table 1), and mean
predose pain intensity measured using VAS was high in both
groups. Baselines for outcome measures, where relevant, are
shown (see Appendix S1 and Table S1).
Primary outcomes
Women in the diamorphine group had modestly better
pain relief scores measured by VAS compared with pethi-
dine at 60 minutes and summarised over the whole 3-hour
period (Table 2 and Figure 2). However for the latter out-
come there was a statistically significant interaction
between time and pain relief group (P = 0.001), with fur-
ther post hoc analyses indicating that the modest improved
pain relief was mostly between the 30- and 60-minute
time-points (Figure 2, and see Supplementary material,
Table S2). There was no statistically significant difference
in analgesic effect at 60 minutes between primiparae and
multiparae (parity and study drug interaction effect
P = 0.94). Of note, from the 60-minute measurement
onwards there was significantly more missing data in the
pethidine group than the diamorphine group (for example
19% versus 10% at 60 minutes, 53% versus 34% at
120 minutes). The difference in quantity of missing data
was largely because the women in the pethidine group
tended to deliver earlier. A second dose of study drug was
requested by 87 women (36%) in the diamorphine group
and 55 women (23%) in the pethidine group (P = 0.003).
There were no significant differences in the neonatal
primary outcome measures of neonatal resuscitation and
Apgar scores < 7 at 1 minute (Table 2).
Results for secondary outcome measures are shown in
the Supplementary material (Tables S2 to S5). There was
no difference in analgesia between the drugs according to
the VRS at any time-point although the overwhelming
majority in both groups reported moderate or severe pain
throughout. The midwife VRS for pain relief was statisti-
cally significantly better in the diamorphine group within
the first hour after the dose. More women in the diamor-
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phine group were very satisfied with their analgesia com-
pared with the pethidine group (45% versus 34%;
P = 0.053 and P = 0.048 after adjusting for pre-specified
covariates in the supplementary analyses) and this may rep-
resent their improved sense of wellbeing. However, when
asked within 24 hours of delivery, approximately 85% of
women in both groups would have the same analgesia
again. There were few differences in other maternal out-
comes except that women in the diamorphine group were
more likely to have haemoglobin saturation SpO2 < 97% at
60 minutes (P = 0.04) but no women had clinically signifi-
cant hypoxia and none required intervention such as oxygen
supplementation. Also, women in the diamorphine group
were less likely to have vomited at 30 minutes but more
likely to have done so at 90 minutes (P = 0.001 for interac-
tion between measurement occasion and study group). Sup-
plementary analyses adjusting for prespecified covariates
suggested that women in the diamorphine group were more
likely to have one or more nausea events during the whole
3-hour period (P = 0.047). There were no differences in
mode of delivery (see Table S6). There were no statistically
significant differences in neonatal outcomes for the main
analyses. After adjusting for prespecified covariates there
appeared to be more moderate or severe neonatal sedation
in the pethidine group (P = 0.04) 2 hours after delivery.
One unexpected but important observation was that
women in the diamorphine group had significantly longer
labours from first dose to delivery, mean (SD)/median 362
(245)/323 minutes compared with pethidine 280 (228)/
203 minutes, mean difference 82 minutes (95% confidence
interval [CI], 39–124), p < 0.001. The distribution of
labour length exhibited some skewness, but the difference
between the two groups was also significant using the
Mann–Whitney U-test (P < 0.001). In primiparae the
means were 424 minutes and 357 minutes, respectively
(mean difference 67 minutes, 95% CI 12–122 minutes;
after adjusting for centre), and in multiparae were
258 minutes and 155 minutes (mean difference 104 min-
utes, 95% CI 52–156 minutes). Further post hoc analysis
suggested that labour was more likely to have been aug-
mented after randomisation in the diamorphine group
(28% versus 18%, P = 0.01). The prolongation of delivery
by diamorphine remained statistically significant when the
analysis was confined to those not augmented after ran-
domisation (55 minutes, 95% CI 14–97), those not having
an epidural (68 minutes, 95% CI 27–108), and those with
an occiput anterior presentation (87 minutes, 95% CI 35–
139). Mean (SD) area under the curve of pain VAS scores
was 13.8 (6.2) in the diamorphine group and 12.7 (6.8) in
the pethidine group, mean difference 1.2 (95% CI 0–2.4,
P = 0.046), suggesting that overall, although women in the
diamorphine group had modestly better short-term pain
relief they experienced more pain over the duration of
labour due to their longer labours.
Figure 1. CONSORT flow chart—IDvIP Trial dated 13 Nov 2013..
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Discussion
Main findings
To optimise the objectivity of pain measurement, we used a
number of different measures: VAS and VRS for pain inten-
sity scored by the women, midwife VRS for pain relief and
maternal satisfaction.14,15 From the VAS, 7.5 mg diamor-
phine i.m. provided, on average, 1 cm better pain relief than
150 mg pethidine i.m., mostly in the period 30–60 minutes
after administration. Although this was the effect size speci-
fied in the sample size calculation, the clinical significance
may be questioned. Some have suggested that the minimum
difference in pain that can be subjectively measured by
women is 1.3 cm, 1.4 cm or 1.8 cm.16–18 Further, expressed
as standardised effect size, the difference is 0.39; a small to
medium effect. We have therefore described the 1-cm effect
as modest.16 For the VRS, the majority of women in both
groups rated their pain as moderate or severe intensity
throughout the study period. Women who received di-
amorphine showed greater levels of satisfaction with their
analgesia but approximately 85% of women in both groups
would choose the same analgesia in a future labour when
questioned within 24 hours of delivery.
A significant finding of this trial was that women in the
diamorphine group had significantly longer labours from
first dose to delivery (mean difference 82 minutes). The
area under the curve analysis that takes into account both
levels of pain intensity and length of labour suggested that
although diamorphine gave modestly improved short-term
analgesia, overall women who received diamorphine experi-
enced more pain over the duration of the labour as a result
of their longer labours.
There were no significant differences in the neonatal pri-
mary outcomes of the need for resuscitation or Apgar
scores <7 at 1 minute between the two groups. This was in
contrast to the findings by Fairlie et al., who found that
the Apgar scores at 1 minute were significantly lower in
the pethidine group.10 There were minimal differences in
maternal and neonatal secondary adverse effects.
Strengths and limitations
To our knowledge this is the largest adequately powered
randomised controlled trial comparing pain relief and
adverse effects between pethidine and diamorphine for
analgesia in labour, and these are the most commonly used
i.m. opioids for labour pain in the UK. Pethidine is the
commonest opioid analgesic used worldwide. We acknowl-
edge that the analgesic effect of a fixed dose may depend
upon factors such as maternal weight; however, the doses
used in the trial are those regularly used nationally in the
Table 2. Primary outcome measures
Maternal Diamorphine Pethidine Mean difference (95% CI) P-value
Mean (SD) Mean (SD)
First dose—reduction from baseline in pain VAS @ 60 minutes 2.2 (2.4) 1.2 (2.7) –1.0 (–1.5 to –0.5) <0.001
First dose—reduction from baseline in pain VAS over 3 hours See Table S2 See Table S2 –0.7 (–1.1 to –0.3) <0.001
Neonatal n (%) n (%) Odds ratio (95% CI) P-value
Needed resuscitation 43 (18%) 44 (19%) 1.06 (0.67 to 1.69) 0.79
Apgar score < 7 at 1 minute 42 (17%) 36 (15%) 0.86 (0.53 to 1.39) 0.53
Table 1. Baseline characteristics—demographic and pregnancy
variables
Diamorphine
(n = 244)
Pethidine
(n = 240)
Maternal age (years),
mean (SD)
28.7 (6.1) 28.7 (5.6)
Parity, n (%)
0 153 (63%) 149 (62%)
1 62 (25%) 63 (26%)
2+ 29 (12%) 28 (12%)
Gestational age (weeks),
mean (SD)
40.3 (1.3) 40.3 (1.2)
Weight (kg), mean (SD) 81.7 (14.1) 84.3 (14.3)
Cervical dilation at first
request for analgesia (cm),
mean (SD)
4.6 (1.6) 4.6 (1.5)
Time between contractions
(minutes), mean (SD)
3.6 (0.9) 3.7 (0.8)
Labour induced n (%) 93 (38%) 96 (40%)
Fetal position, n(%)
OA 141 (58%) 147 (62%)
OP 60 (25%) 47 (20%)
Transverse 39 (16%) 45 (19%)
Other 3 (1%) 0 (0%)
Pain VAS
Mean (SD) 8.1 (1.6) 8.0 (1.7)
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UK and the weight ranges in both arms of the trial were
comparable.11 Strengths of the trial include concealed allo-
cation of study drugs, blinding of researchers (including
statistician) and clinical staff, the broad range of outcome
measures employed and publication of the trial protocol
before completion and analysis of the trial results. The trial
was powered to detect a 50% change in primary neonatal
outcomes. It is possible that the trial missed smaller clini-
cally important effects, although estimates of effect size
derived from the trial did not indicate this to be the case.
There was some evidence in the supplementary analyses
that neonates of women who received pethidine were more
sedated at 2 hours and further longer-term observations
would have informed us if this influenced their subsequent
feeding behaviour and other longer-term adverse effects of
both analgesics. This trial was not designed to study the
longer-term adverse effects of these opioid analgesics in
neonates. We have therefore not used other measures of
neonatal health such as neuroadaptive capacity scores.
For the analysis of pain scores, we are unable to rule
out bias resulting from women in the pethidine group
tending to have shorter labours, and so being less likely to
contribute to the analysis after the 30-minute time-point.
The impact on the results is not known. Four primary out-
comes (two maternal and two neonatal) were specified,
increasing the possibility of type 1 error. Two were statisti-
cally significant. Under the null hypothesis that the two
groups give identical outcomes, the probability that two
or more independent outcome measures are statistically
significant is 0.01 (i.e. unlikely).
Interpretation in the light of other evidence
In contrast to the smaller trial by Fairlie et al.10 this trial
did not confirm that diamorphine resulted in fewer mater-
nal, fetal, and neonatal adverse effects than pethidine. Fur-
thermore, the Fairlie trial only found significant pain relief
at 1 hour in multiparous but not nulliparous women who
received diamorphine compared with those receiving pethi-
dine. As outlined above, a clinically and statistically signifi-
cant finding was that women who received diamorphine
tended to have longer labours by an average of 82 minutes
(67 minutes for primiparae and 104 minutes for multipa-
rae). This persisted when we excluded confounding factors
that might affect the duration of labour such as abnormal
foetal position, use of epidural analgesia and augmented
labour. Using forty-four primary and secondary outcomes,
we cannot exclude the possibility of type 1 error, though
the P-value was small and remained significant after apply-
ing a Bonferroni correction (P < 0.05).
The prolongation of labour following diamorphine anal-
gesia has been noted but not explained by other research-
ers.19,20 Oxytocin secretion is inhibited at the hypothalamus
and the posterior pituitary by both l and j agonists.21 The
mechanism for the prolongation of labour in the absence of
obstetric factors is most likely a result of the effect of
opioid metabolites on the reduction of oxytocin release
from the pituitary gland. Overall, the greater l agonist
effect of diamorphine (via morphine metabolite) compared
with pethidine (predominantly j agonist) and the conse-
quent greater inhibition of oxytocin release by diamorphine
may explain the difference in effect of the two drugs on
duration of labour.
Conclusions
This trial shows that there was a modest, short-term differ-
ence in the analgesia provided by 7.5 mg i.m. diamorphine
compared with 150 mg i.m. pethidine for labour pain. The
size and duration of this difference is of questionable clini-
cal value. Further, diamorphine tends to prolong labour,
resulting in women having greater total pain over the dura-
tion of labour. There were minimal, directionally inconsis-
tent differences in short-term maternal and neonatal
secondary outcomes between the two drugs. Diamorphine
is approximately three times more expensive than pethidine
and diamorphine use is largely limited to the UK. This trial
does not support the use of diamorphine for labour pain.
Future research
We suggest there is a need for an adequately powered study
to ascertain the mechanism of prolongation of labour by
diamorphine and other opioids. We also suggest that the
longer-term effects of diamorphine versus pethidine on the
neonate should be ascertained.
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Commentary on ‘Why bother studying single shot opioids for
labour analgesia?’
Wee et al. have conducted a blinded randomised controlled trial (RCT) comparing intramuscular diamorphine with
intramuscular pethidine for labour analgesia. They report that diamorphine provides (very) slightly better analgesia
with perhaps slightly better maternal satisfaction and less vomiting. A secondary finding was that women assigned to
the diamorphine group had significantly longer labours (delivery ~ 6 hours after dosing compared with ~ 4.5 hours
for pethidine). They conclude that the only marginally better analgesia with diamorphine, combined with evidence of
prolongation of labour, suggests that pethidine should still be the opioid of choice for labour analgesia.
As an obstetric anaesthesiology practitioner and researcher in the USA, I have never used diamorphine, which is not
available here, but am not surprised at the results of this study, which show that neither opioid leads to much analge-
sia. At maximum effect, the mean visual analogue scale score for the diamorphine group had decreased from 8 to 6,
and the pethidine group from 8 to 7. Although this may be statistically detectable, a decrease in pain scores to 6–7 for
half an hour hardly qualifies as ‘analgesia’. It is somewhat disheartening to this obstetric anaesthesiologist that postpar-
tum patient ‘satisfaction’ with analgesia was ~ 85%, confirming the common finding that many women are relatively
pleased with any attempt at analgesia, once they have delivered a healthy baby. A reasonable conclusion from this study
and multiple others would be that no single intramuscular dose of any opioid results in reasonably safe but effective
analgesia for labour. Infusions of remifentanil or patient-controlled infusions of pethidine at much higher doses (Alex-
ander et al. Anesth Analg 2001;92:1524–8) can provide better analgesia than that seen in this study but with significant
side-effects. Neuraxial techniques routinely result in visual analogue scale scores decreasing from the 7–10 to the 0–3
range. Between 60 and 65% of American women receive neuraxial analgesia, and the practice of using intramuscular
opioids for women in active labour is disappearing from most larger US labour and delivery suites. The difference in
practice regarding parenteral opioids on the two sides of the Atlantic is interesting, and surely reflects contributions of
manpower and staffing patterns, culture, expectations and funding mechanisms.
The secondary finding of the study is more intriguing; that either diamorphine prolongs labour, or pethidine short-
ens it. A similar but smaller study more than a decade ago did not find this difference (Fairlie et al. BJOG
1999;106:1181–7), so caution is warranted in accepting this secondary outcome. However, there have been scattered
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reports of pethidine speeding labour or cervical dilatation (Tournaire et al. J Gynecol Obstet Biol. 1980;9:261–6; Leigh-
ton et al. Am J Obstet Gynecol 2002;186:S69–77), and it has been suggested that a labour-enhancing effect of pethidine
could explain some of the results of studies that suggest a labour-slowing effect of neuraxial analgesia when compared
with a group receiving pethidine. Considering that we still really do not understand what initiates and maintains the
labour process, further investigation of the reality and possible mechanism of such an effect would seem worthwhile.
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Mini commentary on ‘Comparison of the efficacy of intramuscular
diamorphinewith intramuscular pethidine in labour‘
Wee et al. present a timely, well-designed trial to compare the efficacy of intramuscular diamorphine with intramuscular
pethidine in labour. Pethidine (meperidine), developed in Germany during the First World War, is a synthetic opioid
that is widely used to provide intramuscular analgesia in labour despite a paucity of data to suggest that it is particularly
effective for this purpose (Olofsson et al. Br J Obset Gynaecol 1996;103:968–72). The overwhelming majority of prospec-
tive trials report that pethidine is, at best, a poor analgesic in labour, and is probably less effective than Entonox (nitrous
oxide) or transcutaneous electrical nerve stimulation (Harrison et al. Acta Obstet Gynecol Scand 1987;66:9–14). At the
same time, the detrimental maternal and neonatal side effects have been widely reported.
Over the years, a number of other synthetic opioids have been developed as intramuscular alternatives with the prom-
ise of greater efficacy and reduced side effects for mother and baby—meptazinol (Meptid), pentazocine and nalbuphine
for example. None have demonstrated clinical benefit. More recently, diamorphine, though not available for clinical use
in many developed countries, has increased in popularity on labour wards in the UK. However, this is based largely on
anecdotal reports and little robust evidence—hence the importance and timeliness of this paper.
The authors report a small ‘statistically’ significant reduction in pain as measured on a 10-cm visual analogue scale in
the diamorphine group–1 cm at an hour and 0.7 cm over 3 hours. However, the clinical significance of this numerical
reduction, as admitted by the authors, is very little; as shown by the verbal rating measurement of pain in which the
overwhelming majority of all labouring mothers in the study describe their pain as moderate to severe throughout,
regardless of which opioid they received. Of more concern, the study suggests that labour is prolonged in the diamor-
phine group by an average of 82 minutes—very significant both statistically and clinically. Hence, overall, the mothers
in the diamorphine group suffered more. Neonatal side effects vary little, but it is important to note that data were only
collected in the first few hours after delivery and no longer-term outcomes were investigated. To top all this, the authors
point out that diamorphine is three times the price of pethidine.
Although it might be important to examine the long-term neonatal side effects and might be of interest to understand
the mechanism by which labour may be prolonged, the take-home message from this study is clear: diamorphine should
not be offered for intermittent intramuscular analgesia in labour. Indeed, perhaps it is time to reconsider the role any
intramuscular opioid in this clinical setting.
Disclosure of interests
No interests to declare.&
M Scrutton
Department of Anaesthesia, St Michael’s Hospital, Bristol, UK
ª 2013 The Authors. BJOG An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of
Royal College of Obstetricians and Gynaecologists. 455
IDvIP Trial: diamorphine vs pethidine for labour analgesia
Journal club
Scenario
On the labour ward, a woman in labour (G1 P0 at 40 weeks of gestation with no other medical history) has been using
Entonox for labour analgesia. She is now requesting additional analgesia, but does not want epidural analgesia. How
would you manage her pain?
Description of research
Participants Women in active labour requiring opioid analgesia for labour pain
Intervention Intramuscular diamorphine (7.5 mg), maximum two doses
Comparison Intramuscular pethidine (150 mg), maximum two doses
Outcomes Maternal: reduction in pain intensity from baseline at 60 minutes and over 3-hour period after drug administration
Neonatal: requirement for resuscitation and Apgar score at 1 minute
Studydesign 1 : 1 Double-blind randomised controlled trial
Discussion points
1. What analgesia advice do you currently give to women in labour who request opioid analgesia?
2. How did the researchers determine the dosage of the opiates used? Is it similar to your current practice?
3. What are the purposes of block randomisation and stratification in this trial?
4. Define allocation, concealment and blinding in a randomised controlled trial—refer to the Cochrane handbook online
(http://handbook.cochrane.org). Are they adequate in this trial?
5. What is the potential clinical relevance of the prolongation of labour observed in this trial?
6. Can you briefly summarise the results of this trial? How would the results of this trial influence your practice? (Data S1)
EYL Leung
Women’s Health Research Unit, Queen Mary, University of London, London, UK
Join us at #BlueJC: Follow @BJOGTweets to stay updated on #BlueJC sessions or email bjog@rcog.org.uk to
host a journal club on Twitter. Find out more on our journal club page by visiting bjog.org&
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